Results 61 to 70 of about 4,744 (194)

Phytochemicals as Multitarget Therapeutics in Pancreatic Cancer: Mechanisms, Clinical Evidence, and Translational Challenges

Phytotherapy Research, EarlyView.
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is aggressive and often diagnosed late, making treatment challenging. This review highlights the potential of phytochemicals, such as curcumin and quercetin, as multitarget agents that influence key carcinogenic pathways. These compounds exhibit anticancer effects by inhibiting processes
Md. Rezaul Islam, Abdur Rauf, F. M. Shourav, Hanan A. Ogaly, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Kamala Badalova, Marcello Iriti   +7 more
wiley   +1 more source

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients [PDF]

, 2019
Purpose Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities.
Okonta, Leroy, Papadatos-Pastos, Dionysis, Mansi, Janine, Kapiris, Matthaios, Karapanagiotou, Eleni, DeSouza, Karen, Marinaki, Anthony, Stavraka, Chara, Pouptsis, Athanasios, Charlton, Philip   +9 more
core   +1 more source

Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy: a matched-pair analysis [PDF]

, 2023
PURPOSEDPYD-guided fluoropyrimidine dosing improves patient safety in carriers of DPYD variant alleles. However, the impact on treatment outcome in these patients is largely unknown.
Droogendijk, H.J., Baars, A., Henricks, L.M., Creemers, G.J., Knikman, J.E., Mathijssen, R.H.J., Gelderblom, H., Valkenburg-van Iersel, L., Poel, M.H.W. van der, Beijnen, J.H., Imholz, A.L.T., Guchelaar, H.J., Portielje, J.E.A., Meulendijks, D., Swen, J.J., Schellens, J.H.M., Lunenburg, C.A.T.C., Vulink, A., Cats, A., Wilting, T.A., Man, F.M. de, Lopez-Yurda, M., Mandigers, C.M.P.W., Nieboer, P.   +23 more
core   +1 more source

Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket

British Journal of Pharmacology, EarlyView.
NLRP3 is a promising inflammatory target, but existing inhibitors lack diversity and brain penetrance, and none are approved. Using chemoproteomics, we discovered a novel series that binds to Cys463 in a previously uncharacterized pocket. Compounds showed nanomolar potency, brain exposure, and in vivo suppression of IL‐1β, supporting neuroinflammatory ...
Donald C. Rogness, Evelyn P. Sievert, Vincent F. Vartabedian, Steffen M. Bernard, Erick Aitchison, William Tao, Mikaela Lindvall, Jing Qian, Christie L. Eissler, Brian E. Nordin, Benjamin D. Horning, Cian Kingston, Kelsey N. Lamb, Joshua C. Bell, Bingwen Lu, Jonathan Pollock, Jun Shi, Roli Khattri, David S. Weinstein, Matthew P. Patricelli, Brian N. Cook, Gabriel M. Simon   +21 more
wiley   +1 more source

Population-specific DPYD variants and fluoropyrimidine toxicity risk: an analysis using public genomic databases

Clinical Medicine
Introduction: Fluoropyrimidines (FP), including 5-fluorouracil (5-FU) and capecitabine, are widely used chemotherapeutic agents. However, their toxicity varies significantly among patients, often because of genetic differences in DPYD, which encodes ...
Suvam Banerjee, Souvik Sengupta
doaj   +1 more source

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer

BMC Cancer, 2021
Background Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine toxicity within European ...
Miguel Cordova-Delgado, María Loreto Bravo, Elisa Cumsille, Charlotte N. Hill, Matías Muñoz-Medel, Mauricio P. Pinto, Ignacio N. Retamal, María A. Lavanderos, Juan Francisco Miquel, Maria Rodriguez-Fernandez, Yuwei Liao, Zhiguang Li, Alejandro H. Corvalán, Ricardo Armisén, Marcelo Garrido, Luis A. Quiñones, Gareth I. Owen   +16 more
doaj   +1 more source

Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics [PDF]

, 2019
Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are among the most frequently prescribed anticancer drugs. They are inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD).
Lunenburg, C.A.T.C.
core  

Diagnostic and therapeutic strategies for fluoropyrimidine treatment of patients carrying multiple DPYD variants [PDF]

, 2018
DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical care. Without phasing information (i.e., allelic location of variants), current genotype-based dosing guidelines cannot be applied to patients carrying multiple ...
Carin A. T. C. Lunenburg, Mathijssen, R.H.J., Lunenburg, Carin A.T.C., Mathijssen, Ron H.J., van Kuilenburg, André B. P., Hans Gelderblom, Gelderblom, Hans, Guchelaar, Henk Jan, van Kuilenburg, André B.P., Schellens, J.H.M., Lunenburg, C.A.T.C., Linda M. Henricks, Mathijssen, Ron H.J.; id_orcid, Ron H. J. Mathijssen, Swen, Jesse J., Mathijssen, Ron H. J., Jesse J. Swen, Henricks, L.M., Lunenburg, Carin A. T. C., Schellens, Jan H. M., Guchelaar, Henk-Jan, Gelderblom, H., Henk-Jan Guchelaar, André B. P. Van Kuilenburg, Henricks, Linda M., Guchelaar, H.J., Swen, J.J., Schellens, Jan H.M., Kuilenburg, A.B.P. van, Jan H. M. Schellens   +29 more
core   +2 more sources

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source

Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells [PDF]

Clinical Cancer Research, 2004
Abstract Purpose: Dihydropyrimidine dehydrogenase (DPD), the initial rate-limiting enzyme in the degradation of 5-fluorouracil (5-FU), is known to be a principal factor in clinical responses to the anticancer agent 5-FU, and various reports have clearly demonstrated that DPD activity is closely correlated to mRNA levels.
Takuya, Noguchi, Keiji, Tanimoto, Tatsushi, Shimokuni, Kei, Ukon, Hiroaki, Tsujimoto, Masakazu, Fukushima, Tsuyoshi, Noguchi, Katsunobu, Kawahara, Keiko, Hiyama, Masahiko, Nishiyama   +9 more
openaire   +2 more sources